From Spot Supply to Strategic Control: What Bicycle’s ²¹²Pb Infrastructure Strategy Signals for the Future of TRP Supply Security

3:30 pm - Thursday 3rd December 2026

  • Assessing the therapeutic potential of Lead-212 and the clinical rationale supporting its continued development
  • Exploring the logistical and supply challenges associated with short half-life isotopes and how developers can successfully navigate them
  • Understanding the balance between operational complexity and potential clinical advantages when selecting radionuclides

Speakers:

Chief Medical Officer
Bicycle Therapeutics plc